Roche has signed an agreement with DalCor Pharmaceuticals (DalCor) to develop a companion diagnostic (CDx) test for acute coronary syndrome (ACS).
The CDx test will be used in a Phase III clinical trial to evaluate the clinical efficacy of dalcetrapib, a therapeutic from DalCor, and will target patients with a specific genotype who have recently experienced ACS.
In addition, the test will assist in determining if a patient is eligible to receive the therapeutic treatment.
Roche Molecular Diagnostics head Paul Brown said: "Our first companion diagnostic test in cardiovascular disease represents a significant innovation and leverages our expertise in developing FDA approved CDx tests.
"Working with DalCor is a good opportunity for us to enter this market and deliver on our mission of personalised healthcare."
DalCor Pharmaceuticals CEO Robert McNeil said: "The possibility of reducing morbidity and mortality for patients who have experienced ACS by identifying genetic markers that can respond to therapy, is an exciting prospect and one that we are eager to be a part of.
"The DalCor and Roche collaboration for the genetic testing is the right combination for successful execution of the Phase III trial."
Dalcetrapib is an investigational medicine, and according to a published analysis by the Montreal Heart Institute, it has the potential to lower cardiovascular morbidity and mortality by up to 39% in patients with a specific genetic profile.
Caused due to the sudden blockage of the blood supply to the heart muscle, ACS affects patients worldwide, and accounts for more than one million hospital admissions annually in the US.